Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by bluemoons20on Mar 26, 2024 3:26pm
59 Views
Post# 35953757

TakeOver

TakeOverBoy   - this  is  sure a great possible windfall  for  Andrew.  This is his best  shot at getting his  money  back  and  leaving the  other shareholders with almost nothing!!

As  noted  , something may have already have been worked out.  Maybe  he  talked with the new head of Shiesiedo   and  they will make another  try at testing.  - of successful  the  value could be  huge  and the  shareholders  are capped @  $2   instead of maybe  $10  to $20.

The other issue is  how do  the  shareholders get their 8%  (if it ever comes)??  Is someone keeping a list of shareholders   and how long  does this  last??  6  months  or  30 years.   A lot  of details are lacking here.  

I  would reluctantly  be prepared  to  vote  to allow the asset  transfer  if  Andrew  pays the other shareholders $2  per share right now   and we call it  a decade!!

GLTA
<< Previous
Bullboard Posts
Next >>